IXT-002

IXT-002 is an investigational inhalation therapy being developed by invoX Pharma, a subsidiary of Sino Biopharmaceutical, for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The drug is delivered using the proprietary Softhaler® platform, which is a multi-dose, propellant-free dry powder inhaler (DPI) technology designed to optimize lung deposition and simplify the inhalation process for patients. While the specific active pharmaceutical ingredient and molecular target of IXT-002 have not been publicly disclosed, the candidate is a key part of invoX's respiratory pipeline, which focuses on leveraging advanced delivery technologies to improve the treatment of chronic lung diseases. The Softhaler® device is engineered to provide consistent dosing across a range of inspiratory flow rates, potentially offering a more reliable delivery method for patients with compromised lung function.